BACKGROUND: Physical activity (PA) has been linked to a lower risk of developing and dying of cancer, yet many cancer survivors do not exercise. In the current study, the authors evaluated the impact of the LIVESTRONG at the YMCA exercise program, available at Young Men's Christian Associations (YMCAs) across the United States, on PA, fitness, quality of life, fatigue, body composition, serum biomarkers, and program safety in cancer survivors. METHODS: Cancer survivors were recruited through the Yale Cancer Center and the Dana-Farber Cancer Institute and randomized to a 12-week, twice-weekly LIVESTRONG at the YMCA exercise program at YMCAs in Connecticut or Massachusetts or to a control group. Questionnaires, dual-energy x-ray absorptiometry scans, 6-minute walk tests (6MWTs), and a fasting blood draw were completed at baseline and at 12 weeks. Intervention effects were evaluated using mixed model repeated measures analysis, with changes at 12 weeks in PA and 6MWT as the primary endpoints. RESULTS: A total of 186 participants were randomized (95 to the exercise group and 91 to the control group). The majority of patients were diagnosed with AJCC stage I to II cancer and 53% had breast cancer. Participants randomized to the LIVESTRONG at the YMCA program experienced increases in PA (71% exercising at 150 minutes/week vs 26% of controls; P<.05) and improvements in the 6MWT (group difference: 28.9 meters [95% confidence interval, 0.3-49.0; P 5.004]) and quality of life (group difference: 2.6 [95% confidence interval, 0.1-5.0; P 5.04]). No adverse events were reported. CONCLUSIONS: The LIVESTRONG at the YMCA exercise program has the potential to impact thousands of survivors across the YMCA network and could lead to improvements in disease and psychosocial outcomes in the growing population of cancer survivors.
INTRODUCTION
Physical activity (PA) has been linked to a lower risk of both developing and dying of cancer. [1] [2] [3] [4] Studies have demonstrated that individuals who are physically active are 20% to 40% less likely to develop cancers of the breast, prostate, and colon, and growing research has suggested that the risk of cancer-related death could be up to 50% lower in those who exercise regularly after a cancer diagnosis. 1 Although to the best of our knowledge there are no randomized trials to date testing the impact of increased PA on the risk of cancer recurrence or mortality, many studies have evaluated the benefits of exercise interventions in cancer survivors, demonstrating that exercise improves quality of life (QOL), fatigue, fitness, body composition, mood, and biomarkers linked to cancer risk and outcomes. 1, [5] [6] [7] [8] Given the benefits of exercise in individuals with cancer, guidelines from the American Cancer Society and the American College of Sports Medicine (ACSM) recommend that cancer survivors engage in 150 minutes per week of moderate-intensity aerobic exercise (or 75 minutes/week of vigorous-intensity aerobic exercise) and 2 strength training sessions per week, as well as decreased sedentary time. 5, 6 Despite these recommendations, < 30% of individuals diagnosed with cancer are reported to engage in recommended levels of PA. 9, 10 To provide an opportunity for cancer survivors to experience the many benefits of exercise after a cancer diagnosis, programs are needed to help cancer survivors exercise in a safe setting that provides support to meet their unique needs. Although numerous studies have been conducted to date, to our knowledge the vast majority of trials have involved supervised exercise programs administered at a health care facility, typically enrolling <100 patients. Although these studies generally have reported significant increases in PA as a result of program participation, this model is difficult to scale for the large population of cancer survivors currently living in the United States, especially those who live in less populated rural areas without easy access to a health care facility.
Currently, approximately 80% of US households are within 5 miles of a Young Men's Christian Association (YMCA); the YMCA serves > 22 million members each year in >10,000 communities. 11 This broad network provides a unique ability to disseminate healthy lifestyle programs across the Unites States. In 2008, the LIVE-STRONG Foundation partnered with YMCA in the United States (Y-USA) to develop and offer safe and effective PA options for those living with, through, and beyond cancer. 11 The LIVESTRONG at the YMCA exercise program is a 12-week, small group-based exercise program comprised of twice-weekly supervised exercise sessions led by a YMCA trainer. Participating YMCAs must demonstrate their capacity and willingness to develop and sustain LIVESTRONG at the YMCA, offering the program at little or no cost to participants.
The LIVESTRONG at the YMCA exercise program is currently offered in 478 (18%) YMCA branches across the country and has served >37,000 cancer survivors since its creation in 2008. However, to the best of our knowledge, the safety and effectiveness of this program has yet to be tested. Thus, the purpose of the current study was to provide a comprehensive evaluation of the physical and psychological impact, as well as safety, of the LIVE-STRONG at the YMCA exercise program for cancer survivors to determine whether the impact of this community-based program was similar to the benefits observed with regard to increasing PA, fitness, and QOL in hospital-based exercise studies in cancer survivors.
MATERIALS AND METHODS

Participants and Recruitment
Eligibility criteria for the current study were similar to those of the LIVESTRONG at the YMCA exercise program (ie, individuals with a prior cancer diagnosis who received medical clearance from a health care provider to participate in the program). Other study-related eligibility criteria included the ability to complete forms and understand instructions in English, a willingness to be randomized to and to attend an exercise program at a participating YMCA, and to attend baseline and 3-month clinic visits.
Cancer survivors were recruited between April 2013 and October 2014 from Smilow Cancer Hospital at Yale New Haven Health (Yale) and Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts using multiple strategies including review of patient lists and tumor registries. Interested subjects were screened by study staff either in person or by telephone, and if they were determined to be eligible, were then scheduled for a baseline visit.
After baseline data collection, participants were randomized to immediate participation in the LIVE-STRONG at the YMCA exercise program or to a wait-list control group using a random permuted block design of varying block size in a 1:1 ratio. Patients were stratified based on study site and current use of chemotherapy (yes vs no). The Yale University School of Medicine Human Investigation Committee and Dana-Farber/Harvard Cancer Center Institutional Review Board approved all procedures, including written informed consent.
The current study is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02112149).
LIVESTRONG at the YMCA Exercise Program
Participants were randomized to the LIVESTRONG at the YMCA exercise program at one of the participating YMCAs in Connecticut or Massachusetts.
11 Study participants were incorporated into standard, ongoing, regular LIVESTRONG at the YMCA exercise program sessions with the sessions led by 2 YMCA fitness instructors who were trained in the basics of cancer etiology, treatment, and survivorship. Trainers worked with each participant to fit the program to their individual needs based on the participant's age, cancer type, and any comorbidities, with the type of exercise and progression in duration or intensity modified accordingly. Two sessions were held each week, each of which lasted 90 minutes. Sessions followed the recommendations of the ACSM 6 for cancer survivors and began with a warmup, followed by aerobic exercise, resistance training exercises, and a cool-down period. The trainers recorded participant attendance, and participants recorded their exercise during the sessions as well as any exercise performed outside of the sessions in a physical activity log book provided by the study.
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Wait-List Control Group
Participants randomized to the wait-list control group were able to initiate the LIVESTRONG at the YMCA exercise program after their 3-month visit. They were allowed to exercise as much as they wished during the waiting period, but were not given instructions or support regarding an exercise program during this time.
Outcome and Covariate Measures
The following measures were collected from study participants during clinic visits at Yale or DFCI at baseline and 3 months.
Demographics and medical history
Self-report questionnaires were used to determine cancer type, date of diagnosis, stage of disease, surgery, radiotherapy, chemotherapy, and endocrine therapy.
Weight and height
Participants were weighed and measured in light indoor clothing, without shoes, rounding up to the nearest 0.1 kg for weight and to the nearest 0.1 cm for height. All measurements were performed and recorded twice in succession, and averaged for analyses.
Physical activity
Participants completed an interview-administered PA questionnaire, assessing the past 3 months of PA including the type, frequency, and duration of 20 activities. 12 
6-Minute Walk Test
The 6-minute walk test (6MWT) is considered a valid measure of cardiorespiratory fitness, with a correlation coefficient of of 0.67 between the 6MWT and oxygen consumption(VO 2 ) peak. 13 Participants wore walking shoes and walked indoors along a long, flat, straight, enclosed corridor on a flat surface for 6 minutes. 13 They were instructed to walk as fast as they could continuously along an area at least 15 meters in length, back and forth, for 6 minutes.
QOL and fatigue
QOL was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire (version 3) (Cronbach a coefficient, .89), 14 and fatigue was assessed through the FACT-Fatigue scale (test-retest correlation coefficient range, 0.84-0.90). 15 Both measures have been found to be valid instruments for use in cancer survivors. 14, 15 Dual energy x-ray absorptiometry scans Dual-energy x-ray absorptiometry scans were performed to assess body fat, lean body mass, and total bone mineral density with a Hologic Discovery scanner (version 3.3.0.1; Hologic Inc, Marlborough, Mass) (coefficient variable, 1.07). All scans were evaluated by a radiologic technician certified in bone density who was blinded to the randomization group.
Blood draw and serum biomarkers
Blood was collected after a 12-hour fast and was stored at 280 8C until assayed. At the time of completion of all data collection, DFCI shipped their frozen samples to Yale, where all blood analyses were conducted. Serum concentrations of insulin were measured using radioimmunoassay kits (Catalog HI-14K; EMD Millipore, Billerica, Mass) and C-reactive protein (CRP) was measured using an automated chemistry analyzer (Alera analyzer; Alfa Wassermann Diagnostic Technologies, LLC, West Caldwell, NJ [Raichem Cliniqa hsCRP Wide Range Reagent Catalogue number 85550]). Baseline and 3-month specimens were assayed simultaneously, and participants from both randomization groups were included in each batch of assays. Samples were measured in duplicate with coefficients of variation for all samples <10%. Laboratory technicians were blinded to treatment assignment.
Safety evaluation/injury questionnaire
Study participants completed a safety evaluation/injury questionnaire at 3 months, which was reviewed in person at the 3-month clinic visit. The questionnaire asked about any falls, muscle or joint injuries, or other injuries, and whether they were a result of the exercise program.
Lymphedema Questionnaire
Breast cancer survivors completed the validated lymphedema questionnaire by Norman et al. 16 
Statistical Analyses
The planned sample size was 200 participants, providing an evaluable sample of 90 participants per group, assuming a 10% attrition rate. This sample size would provide 80% power to detect a difference of 105 minutes per week of exercise between groups with a type 1 error at 0.05, based on a priori estimate of baseline exercise of 2.0 6 4.0 hours per week. Participants were grouped according to the intentionto-treat principle. Intervention effects were evaluated by the differences in the mean changes between baseline and 3 months between the intervention and control groups using the mixed model repeated measure analysis to account for the longitudinal nature of the data and the ability to use all available data to provide a robust estimate based on the assumption of missing at random. We also adjusted for study site (Yale or DFCI) and baseline value of the outcome of interest, and explored a priori effect modification by sex, cancer site, whether the patient currently was receiving chemotherapy (yes/no), baseline PA level, body mass index (BMI), and time from diagnosis. In addition, for exercisers only, we examined changes in these endpoints based on attendance at the LIVESTRONG at the YMCA exercise program. Analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC). Statistical significance was set at P<.05 using 2-sided tests. 
RESULTS
Baseline Characteristics
A total of 186 men and women who were diagnosed with cancer were enrolled into the current study (Fig. 1) . Baseline characteristics were similar for both groups (Table 1) . On average, participants were aged 59.3 6 10.4 years, 80% non-Hispanic white, 3.8 6 3.1 years from diagnosis, and with a BMI of 29.0 6 5.7 kg/m 2 , with 53% of the participants diagnosed with breast cancer.
A total of 164 of the 186 enrolled participants completed the study (88%). Study site (3% of dropouts were from Yale and 22% were from DFCI; P<.0001) and race (9% of white participants and 29% of black participants withdrew from the study; P 5 .04) were found to be different between participants who dropped out of the study versus those who completed the study.
Changes in PA and Fitness
A majority of participants were inactive at baseline, with 34% reporting at least the recommended level of 150 minutes per week of PA (Fig. 2) . Participants randomized to the LIVESTRONG at the YMCA exercise program who initiated the program (81 participants) attended on average 83% of the 24 sessions over the 12-week program. At the end of the intervention period, 71% of the participants in LIVESTRONG at the YMCA program reported at least 150 minutes of exercise per week versus 26% of controls (P<.05) (Fig. 2) . Intervention participants increased their amount of exercise by an average of 127.0 minutes per week compared with a decrease of 5.8 minutes per week in the control group (P 5 .0001) ( Table  2 ). Participation in the intervention was found to increase exercise both in participants who were more and those who were less active at baseline (Table 2) .
Participation in the exercise program also led to significant improvements in fitness as measured by the 6MWT. Intervention participants increased the distance that they could walk in 6 minutes by 33.8 meters versus 4.9 meters in the control group (P 5 .004). In addition, improvements in fitness as a result of the exercise program were observed in both participants who were inactive and those who were active at baseline, with participants who engaged in <150 minutes of exercise per week at baseline increasing their distance by 27.7 meters versus 3.4 meters in controls (P<.05), and those reporting >150 minutes of exercise per week at baseline increasing their distance by 39.6 meters versus 10.1 meters in controls (P<.05).
Changes in QOL and Fatigue
The exercise program improved QOL, as assessed via the FACT-G, by 1.6 units versus a decrease in QOL of 1.0 units in the control group (P 5 .039) ( Table 2 ). Although there was no significant impact of the program on fatigue noted in the population as a whole, among participants diagnosed with cancer within the past 3.5 years (median cutpoint), cancer-related fatigue improved by 7.5% in those who exercised versus a slight worsening in controls (P 5 .03) ( Table 3) . A dose-response effect of higher attendance to the exercise program also was found to be associated with greater and statistically significant improvements in QOL and fatigue (Fig. 3) . Baseline characteristics including sex, cancer site (breast cancer vs other), and whether the individual was currently receiving chemotherapy (yes/no) did not appear to modify the effect of exercise on QOL and fatigue.
Changes in Body Composition and Serum Biomarkers
No between-group differences were observed for changes in body composition, insulin, or CRP levels from baseline to 3 months (Table 2) . Although baseline PA levels did not appear to modify the effect of exercise on body composition or serum biomarkers, more favorable changes in body weight, percentage body fat, lean body mass, insulin, and CRP were observed among participants randomized to the LIVESTRONG at the YMCA exercise program who had baseline PA levels >150 minutes per week compared with participants randomized to the control group who were active or inactive at baseline, as well as participants randomized to the LIVESTRONG at the YMCA exercise program who were inactive at baseline.
Safety Evaluation
No injuries were reported over the duration of the study based on an interview-administered survey of musculoskeletal injuries, falls, or general injuries. In the subgroup of patients with breast cancer, 20 of 99 participants (10 of 49 in the exercise group and 10 of 50 in the usual-care group) reported upper body lymphedema at baseline. At 3 months, 3 of the 10 women in the exercise group reported an improvement in lymphedema, with the remaining 7 women reporting no worsening of symptoms. Among women randomized to the control group, 5 of the 10 women reported an improvement in lymphedema, with the other 5 women reporting no worsening of symptoms. Among women without lymphedema at baseline, 2 women in the control group and none in the exercise group reported lymphedema at 3 months.
DISCUSSION
The LIVESTRONG at the YMCA exercise program was found to be effective in improving PA, fitness, QOL, and cancer-related fatigue in a mixed group of patients with cancer, including long-term cancer survivors, newly diagnosed patients receiving adjuvant therapy, and individuals living with advanced disease. Benefits were observed both in patients who were more and those who were less active at baseline. Interest in study participation was high, with 186 participants enrolled within 15 months from 2 centers. Approximately 48% of survivors who were screened for the study ultimately were randomized, which is a rate higher than that noted in many health care facility-based exercise studies in healthy adults and cancer survivors. 17, 18 Previous trials have shown a benefit of exercise in cancer survivors, including improvements in QOL, fatigue, fitness, body composition, and biomarkers linked to cancer risk and outcomes. [6] [7] [8] The current study findings of an average increase of 33 meters or 6.7% in fitness, as assessed via the 6MWT, is considered clinically meaningful. 19 In a recently published meta-analysis of 16 exercise trials among cancer survivors, 8 exercise was found to significantly improve QOL in comparison with usual care in only 8 trials (50%), with a mean between-group difference of 5.55 (95% confidence interval, 3.19-7.90; P<.001). Possible reasons for the greater improvement in QOL noted in those 8 exercise trials compared with the improvement in the LIVESTRONG at the YMCA exercise program is because of differences in the frequency of exercise sessions. In the meta-analysis, exercising > 2 times per week was associated with a greater benefit in QOL and fatigue. The timing of the intervention also was important, because exercise improved QOL and fatigue significantly more often in studies taking place during cancer treatment compared with studies performed after treatment. This most likely can be explained by the negative impact of radiotherapy and chemotherapy on fatigue and the positive effect of exercise on this factor. We also observed a greater benefit of exercise on QOL and fatigue among participants in the LIVESTRONG at the YMCA exercise program who recently completed adjuvant treatment and were diagnosed within the past 3.5 years compared with participants diagnosed >3.5 years previously and therefore further out from completing adjuvant treatment. We found a clinically meaningful between-group difference of 4.1 and 3.5, respectively, in QOL and fatigue among participants diagnosed within the past 3.5 years compared with a between-group difference of 1.2 and 1.3, respectively, in QOL and fatigue among participants diagnosed >3.5 years previously.
Although previous studies have provided an important rationale for the inclusion of exercise as a significant part of the care of cancer survivors, to the best of our knowledge they do not provide much information regarding effective means of implementing exercise programs in large groups of survivors in the community. The LIVE-STRONG at the YMCA exercise program provides significant benefits for cancer survivors through a communitybased exercise program that is available in hundreds of communities across the Unites States, thereby providing a novel mechanism with which to disseminate high-quality exercise programing to a diverse group of cancer survivors.
The current study also evaluated the safety of the LIVESTRONG at the YMCA exercise program. There has been some controversy regarding the optimal setting in which a patient with cancer or a cancer survivor should initiate an exercise program. The ACSM exercise guidelines do not recommend a medical assessment for cancer survivors before initiating an exercise program due to the increased barriers this may pose to beginning an exercise program, as well as the high benefit/low risk of exercising. 6 However, the LIVESTRONG at the YMCA exercise program requires physician consent before patients can initiate the program in an attempt to further minimize any risks associated with exercise. In the current study, no injuries were reported in either group. In addition, > 50% of the current study participants were women with breast cancer, and there were no additional cases of lymphedema noted in patients without this condition at baseline or new cases of lymphedema in women who already had this condition as a result of participating in the LIVE-STRONG at the YMCA exercise program. Similar to the LIVESTRONG at the YMCA exercise program, none of the 16 exercise trials included in a recent meta-analysis 8 reported adverse effects of exercise.
The current study has several weaknesses that should be noted. The current study population was comprised primarily of non-Hispanic white, highly educated survivors of breast cancer. We also focused on the immediate impact of the intervention on PA and other outcomes, and did not have longer-term data regarding the maintenance of changes in PA and other measures over time. Last, there was no apparent effect of the LIVESTRONG at the YMCA exercise program on body composition or serum biomarkers. The current study enrolled both physically active and inactive participants, with a range of BMI levels and different cancer types, which increase the generalizability of the study findings yet may confound our ability to determine an effect of exercise on body composition, insulin, and CRP. Future studies are needed to evaluate the dose-response effect of the LIVESTRONG at the YMCA program and whether additional exercise sessions per week or a higher intensity of exercise are necessary. Additional studies are needed that evaluate the maintenance of PA over time, as well as how to improve attendance to the exercise sessions and associated predictors of attendance. Last, it is important to examine the effectiveness of the LIVESTRONG at the YMCA exercise program by geography, race/ethnicity, and socioeconomic status.
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The evaluation of other YMCA chronic disease prevention programs also may assist in the future evaluation and effectiveness assessment of the LIVESTRONG at the YMCA exercise program. Since 2005, the YMCA has worked to become a leading provider of chronic disease prevention programs. In 2010, Y-USA began working with the Diabetes Prevention and Control Alliance to spread and sustain the YMCA's Diabetes Prevention Program through claims-based reimbursements from insurers and employers. Y-USA then worked closely with the American Medical Association to obtain a Current Procedural Terminology code for diabetes prevention programming and helped the local YMCAs secure national provider identification numbers that would allow them to bill health plans for program delivery. In March 2016, the US Department of Health and Human Services announced that a successful 4-year demonstration project that served nearly 8000 Medicare beneficiaries with the YMCA's Diabetes Prevention Program produced significant cost savings for Medicare, thus creating a path for Medicare coverage of the program in 2018. Building on these successes, Y-USA currently is charting a course to achieve similar successes with LIVESTRONG at the YMCA by establishing stronger clinical partnerships, pursuing commercial payers to ensure program accessibility and sustainability, and exploring how YMCAs (and other community-based organizations) can help clinical teams produce improvements in health and cost savings under alternative payment models such as the oncology care model.
The findings of the current study provide important data regarding the physical and psychological benefits, as well as the safety, of the LIVESTRONG at the YMCA exercise program in cancer survivors, and may support the continued implementation of the LIVESTRONG at the YMCA program in YMCA facilities across the country. Given that increasing PA carries the tremendous potential to improve both the length and quality of survival, and to prevent or control the comorbidities and side effects associated with cancer or its treatment, the LIVESTRONG at the YMCA exercise program is an attractive option for cancer survivors throughout the United States and can serve as model for the development of exercise programs for cancer survivors around the world.
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